ADC Development Services Targeting CEACAM5

Antibody-drug conjugate (ADC) is a type of novel anticancer agent developed to selectively deliver a cytotoxic drug to tumors, while minimizing systemic toxicity to healthy tissues. Antibody is one of the critical components of the ADC construction, which can specifically target the tumour-antigen. Besides, potent payload and suitable linker are also important to create a successful ADC. With abundant experience in antibody production and ADCs development, Creative Biolabs provides a full range of ADCs development services targeting CEACAM5. Our professional team is optimized to help you with high-quality and cost-effective service to make your project a success.

Introduction of CEACAM5

CEACAM5 (carcinoembryonic antigen cell adhesion molecule) belongs to anchored glycoprotein encoded by the CEACAM5 gene. It plays important roles in many cell adhesion and cell signaling, which involved in complex biological processes such as cancer, inflammation angiogenesis, and metastasis. CEACAM5 was first found in 1965 in human colon cancer as an oncofetal antigen, it is also highly expressed at the surface of other tumor cells. Thus, CEACAM5 has been considered as a useful biomarker for the treatment of cancers, such as colorectal cancers (CRC). CEACAM5 exists in more than 80% of colorectal cancer cells. Currently, ADCs against CEACAM5 have shown promising effectiveness in colorectal and pancreatic cancer treatments.

The human CEACAM family. Fig.1 The human CEACAM family. (Tchoupa, 2014)

Anti-CEACAM5 ADC in Colorectal Cancer (CRC)

CRC is a common cancer that starts in the rectum or colon. Nowadays, CEACAM5 is becoming a promising target in the ADCs therapy for the CRC treatment. Take SAR408701 (SAR) as an example, it is composed of an anti-CEACAM5 antibody linked to the microtubule-targeting mitosis inhibitor DM4 via a cleavable N-succinimidyl 4-(2-pyridyldithio) pentanoate linker. Pre-clinical studies showed that the ADC has promising anti-tumour activity in CRC. Besides, clinical phase I study results demonstrated that SAR harbors an acceptable safety profile.

Another ADC conjugates the anti-CEACAM5 antibody to the active metabolite of irinotecan, SN-38, through a proprietary linker. Pre-clinical data indicated that this ADC has potent efficacy and limited toxicity compared to free drug irinotecan in colorectal cancer xenografts. After phase I studies in patients with relapsed or refractory metastatic colorectal cancer, the ADC has shown effective outcomes. Therefore, this ADC is currently recommended as third line treatment for relapsed or refractory metastatic colorectal cancer.

The structure of Labetuzumab govitecan (IMMU-130). Fig.2 The structure of an anti-CEACAM5 ADC. (Nanna, 2017)

What Can We Do for You?

In recent years, Creative Biolabs has successfully finished a large number of ADCs design and development projects for our customers all over the world. Our ADCs development services include:

We are confident to provide the high-efficient services and high-quality products to meet our client's specific requirements. If you are interested in our service, please do not hesitate to contact us for more details.

References

  1. Tchoupa, A. K.; et al. Signaling by epithelial members of the CEACAM family-mucosal docking sites for pathogenic bacteria. Cell Communication and Signaling. 2014, 12(1): 27.
  2. Nanna, A. R.; et al. Chemical Assembly of Antibody-Drug Conjugates. Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins. 2017, 1-28.

For lab research use only, not for any in vivo human use.


Related Sections

ADC Development for Gastrointestinal Cancer: Disease Research:
Online Inquiry
Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:
*Verification Code:
Verification code
Click image to refresh the verification code.


Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.


Contact us
USA
 45-1 Ramsey Road, Shirley, NY 11967, USA
 Tel: 1-631-357-2254
 Fax: 1-631-207-8356
 Email:
Europe
UK - Germany
Email:


Inquiry

Top